Milestone Pharmaceuticals Inc. (MIST) Revenue History
Annual and quarterly revenue from 2017 to present
MIST Revenue Over Time (2017–2025)
MIST Revenue Growth History
0 of 3 years with positive growth- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- -66.7%
- FY2023 revenue growth
- -80.0%
- FY2024 revenue growth
- -100.0%
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $238K | — |
| Q4 2025 | $1.5M | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
Multi-year avg. share of annual revenue by fiscal quarter
MIST Revenue Analysis (2017–2025)
Current Revenue & Growth
As of June 28, 2026, Milestone Pharmaceuticals Inc. (MIST) generated trailing twelve-month (TTM) revenue of $1.8 million. The most recent quarter (Q1 2026) recorded $238,000 in revenue, down 84.6% sequentially.
Historical Growth Trajectory
MIST's historical revenue data shows a 3-year CAGR of -32.4%. Milestone Pharmaceuticals Inc.'s highest annual revenue of $15.0 million was recorded in 2021.
Peer Comparison
Compared to Healthcare sector peers — including ACAD (+9.9% YoY), XENE (-100.0% YoY), and INVA (+13.6% YoY). Compare MIST vs ACAD →
MIST Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| MISTCurrent | $2M | - | - | -4041.7% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 XENE | $8M | -100.0% | -25.3% | -4974.3% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 IDYA | $219M | +3118.1% | +62.1% | -72.8% |
MIST Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.5M | - | $1.4M | 92.6% | $-62,485,000 | -4041.7% |
| 2024 | $0 | -100.0% | $0 | - | $-42,102,000 | - |
| 2023 | $1.0M | -80.0% | $1.0M | 100.0% | $-61,098,000 | -6109.8% |
| 2022 | $5.0M | -66.7% | $5.0M | 100.0% | $-59,642,000 | -1192.8% |
| 2021 | $15.0M | - | $15.0M | 100.0% | $-43,073,000 | -287.2% |
| 2020 | $0 | - | $0 | - | $-50,710,000 | - |
| 2019 | $0 | - | $0 | - | $-57,881,000 | - |
| 2018 | $0 | - | $-10,000 | - | $-23,822,000 | - |
| 2017 | $0 | - | $-8,000 | - | $-8,268,000 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MIST — Frequently Asked Questions
Quick answers to the most common questions about buying MIST stock.
Is MIST's revenue growth accelerating or slowing?
MIST TTM revenue: $2M. YoY growth: N/A. 5-year CAGR: N/A.
What is MIST's revenue history from 2017 to 2026?
Milestone Pharmaceuticals Inc. (MIST) revenue history spans 2017 to 2026. TTM revenue as of 2026 is $2M, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is MIST's long-term revenue growth rate (CAGR)?
Milestone Pharmaceuticals Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for MIST.
Why does MIST's quarterly revenue fluctuate?
MIST quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Milestone Pharmaceuticals Inc.'s revenue data from 2017 to 2026 shows full historical quarterly detail on this page.
How is MIST's revenue distributed by segment?
MIST reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does MIST's revenue compare to industry peers?
Milestone Pharmaceuticals Inc. (MIST) with TTM revenue of $2M and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.